Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zezheng Biotechnology is an innovative biopharmaceutical company based in Shanghai, China, specializing in the development of next-generation cell therapies for solid tumors. The company leverages its proprietary Z-CAR technology platform to engineer CAR-T cells designed to overcome the immunosuppressive tumor microenvironment and enhance therapeutic persistence. Its lead program, ZZ-101, is a CAR-T cell therapy targeting Glypican-3 (GPC3) for the treatment of advanced hepatocellular carcinoma. Zezheng is focused on addressing the significant unmet medical needs in oncology by integrating synthetic biology with advanced cell engineering. The company aims to transform the treatment landscape for refractory solid malignancies through its robust R&D pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zezheng Biotechnology.